CVS to Pay $315M in Opioid Prescription Settlement with New Oversight
CVS agrees to pay $315 million and implement new controls over opioid prescriptions.
Why it matters: This settlement highlights increased legal scrutiny on controlled substance dispensing and signals tighter compliance demands for pharmacies and healthcare providers.
- CVS settles for $315 million over unlawful opioid prescription practices between 2013 and 2025.
- The U.S. DOJ accused CVS of violating the Controlled Substances Act and False Claims Act.
- Settlement includes new safeguards like a reporting hotline, monitoring dispensing, and prescriber evaluations.
- CVS denies wrongdoing but commits to enhanced compliance measures under the settlement.
CVS Pharmacy Inc. has agreed to a $315 million settlement to resolve allegations that it filled opioid and other controlled substance prescriptions without legitimate medical purpose from October 17, 2013, through December 2, 2025, according to a U.S. Department of Justice release. The department claimed CVS violated the Controlled Substances Act by unlawfully filling prescriptions and breached the False Claims Act by billing federal healthcare programs for these prescriptions.
The DOJ attributed these violations to CVS’s corporate policies that prioritized sales performance and incentive compensation over patient safety. This included staffing choices and metrics that pressured employees to dispense controlled substances improperly.
As part of the agreement, CVS will enhance its compliance measures through several safeguards. These include establishing a hotline for reporting suspected illegal opioid dispensing, monitoring pharmacy dispensing patterns for anomalies, and evaluating prescribers suspected of inappropriate prescribing practices. These measures aim to prevent future violations and better protect public health amid the ongoing opioid crisis.
While CVS has not admitted any wrongdoing, its General Counsel Thomas Moriarty said settling was in the best interest of all parties involved, including customers and shareholders. Assistant Attorney General Brett A. Shumate emphasized the requirement for CVS to ensure opioids are dispensed only when medically appropriate. Associate Attorney General Stanley E. Woodward Jr. called the settlement a significant milestone in the DOJ's campaign against the opioid epidemic.
The opioid crisis, at its peak, caused over 100,000 deaths annually in the U.S., prompting extensive federal efforts to hold distributors and pharmacies accountable. This settlement adds to over $50 billion in total resolutions by various companies addressing their roles in the epidemic.
By the numbers:
- $315 million — settlement amount agreed by CVS
- October 17, 2013 to December 2, 2025 — period of alleged unlawful dispensing
- Over 100,000 deaths annually — peak impact of the opioid crisis in the U.S.
Yes, but: CVS has not admitted wrongdoing as part of the settlement, illustrating legal risk management despite liability concerns.